Reena H Doshi1, Vivian H Alfonso, Nicole A Hoff, Patrick Mukadi, Sue Gerber, Ado Bwaka, Stephen G Higgins, Guillaume Ngoie Mwamba, Emile Okitolonda, Jean-Jacques Muyembe, Anne W Rimoin. 1. From the *Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California; †Department of Microbiology, University of Kinshasa, School of Medicine, Kinshasa, Democratic Republic of the Congo; ‡Polio Program, Bill and Melinda Gates Foundation, Seattle, Washington; §McKing Consulting Corporation, Expanded Programme on Immunization, Kinshasa, Democratic Republic of the Congo; ¶Opgen, Inc., Gaithersburg, Maryland; ‖Expanded Programme on Immunization, Ministry of Health, Kinshasa, Democratic Republic of the Congo; **Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo; and ††Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Abstract
BACKGROUND: Mumps is an acute viral infection and while the infection is usually mild, complications can lead to permanent sequelae including brain damage and deafness. The burden of mumps is currently unknown the Democratic Republic of Congo (DRC), we therefore assessed susceptibility to mumps infection among children 6-59 months of age. METHODS: In collaboration with the 2013-2014 DRC Demographic and Health Survey, we conducted a serosurvey to assess population immunity to vaccine preventable diseases. Dried blood spot samples were collected from children 6 to 59 months of age and processed at the UCLA-DRC laboratory in Kinshasa, DRC using the Dynex Technologies Multiplier FLEX chemiluminescent immunoassay platform (Dynex multiplex assay, Chantilly, VA). Logistic multivariate analyses were used to determine risk factors for mumps seropositivity. RESULTS: Serologic and survey data were matched for 7195, 6-59 month-old children, among whom 22% were positive and 3% indeterminate for mumps antibodies in weighted analyses. In multivariate analyses, the odds of seropositivity increased with increasing age, female gender, number of children in household, increasing socioeconomic status and province (Kinshasa with the highest odds of positive test result compared with all other provinces). CONCLUSION: These data suggest that mumps virus is circulating in DRC and risk of exposure increases with age. At present, the introduction of a combined measles-mumps-rubella vaccine remains unlikely, as the capacity to maintain adequate vaccine coverage levels for routine immunization must be improved before additional antigens can be considered for the routine immunization schedule.
BACKGROUND: Mumps is an acute viral infection and while the infection is usually mild, complications can lead to permanent sequelae including brain damage and deafness. The burden of mumps is currently unknown the Democratic Republic of Congo (DRC), we therefore assessed susceptibility to mumps infection among children 6-59 months of age. METHODS: In collaboration with the 2013-2014 DRC Demographic and Health Survey, we conducted a serosurvey to assess population immunity to vaccine preventable diseases. Dried blood spot samples were collected from children 6 to 59 months of age and processed at the UCLA-DRC laboratory in Kinshasa, DRC using the Dynex Technologies Multiplier FLEX chemiluminescent immunoassay platform (Dynex multiplex assay, Chantilly, VA). Logistic multivariate analyses were used to determine risk factors for mumps seropositivity. RESULTS: Serologic and survey data were matched for 7195, 6-59 month-old children, among whom 22% were positive and 3% indeterminate for mumps antibodies in weighted analyses. In multivariate analyses, the odds of seropositivity increased with increasing age, female gender, number of children in household, increasing socioeconomic status and province (Kinshasa with the highest odds of positive test result compared with all other provinces). CONCLUSION: These data suggest that mumps virus is circulating in DRC and risk of exposure increases with age. At present, the introduction of a combined measles-mumps-rubella vaccine remains unlikely, as the capacity to maintain adequate vaccine coverage levels for routine immunization must be improved before additional antigens can be considered for the routine immunization schedule.
Authors: Stephen G Higgins; Nicole A Hoff; Adva Gadoth; Andrew Fusellier; Patrick Mukadi; Vivian Alfonso; Christina Randall; Hayley Ashbaugh; Melanie Poncheri; Reena H Doshi; Sue Gerber; Roger Budd; Robert Wolfert; Russell Williams; Emile Okitolonda-Wemakoy; Jean-Jacque Muyembe-Tamfum; Anne W Rimoin Journal: mSphere Date: 2019-08-14 Impact factor: 4.389
Authors: Hayley R Ashbaugh; James D Cherry; Nicole A Hoff; Reena H Doshi; Vivian H Alfonso; Adva Gadoth; Patrick Mukadi; Stephen G Higgins; Roger Budd; Christina Randall; Guillaume Ngoie Mwamba; Emile Okitolonda-Wemakoy; Jean Jacques Muyembe-Tamfum; Sue K Gerber; Anne W Rimoin Journal: Vaccine Date: 2020-02-24 Impact factor: 3.641
Authors: Hayley R Ashbaugh; James D Cherry; Nicole A Hoff; Reena H Doshi; Vivian H Alfonso; Adva Gadoth; Patrick Mukadi; Stephen G Higgins; Roger Budd; Christina Randall; Emile Okitolonda-Wemakoy; Jean Jacques Muyembe-Tamfum; Sue K Gerber; Anne W Rimoin Journal: J Pediatric Infect Dis Soc Date: 2019-12-27 Impact factor: 3.164